Search
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigational[A243351, A243361, L39411] Tixagevimab is not approved for any indication by the FDA. … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Tenofovir alafenamide
go.drugbank.com/drugs/DB09299ApprovedInvestigational[T239] Tenofovir alafenamide is an alanine ester form characterized for presenting low systemic levels but high intracellular concentration. … [A178060] Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal
Pralidoxime
go.drugbank.com/drugs/DB00733ApprovedInvestigationalVet approvedIf given within 24 hours,after organophosphate exposure, pralidoxime reactivates the enzyme cholinesterase by cleaving the phosphate-ester bond formed between the organophosphate and acetylcholinesterase … Pralidoxime is an antidote to organophosphate pesticides and chemicals.
Ganaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigational[L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636] … [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment
Lazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigational[A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.
Synonyms: N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE, 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-Mometasone furoate
go.drugbank.com/drugs/DB14512ApprovedInvestigationalVet approvedMometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions[FDA Label] . It has a glucocorticoid receptor binding affinity 22 times stronger than dexamethasone and highe...
Ioxitalamic acid
go.drugbank.com/drugs/DB13444ApprovedWithdrawn[A33006] Ioxitalamic acid in the salt forms of sodium and meglumine was developed by Liebel-Flarshem Canada Inc and approved by Health Canada in 1995. … [A27209] It is a first-generation contrast media formed by an ionic monomer with a high osmolarity of 1500-1800 mOsm/kg.
Palivizumab
go.drugbank.com/drugs/DB00110ApprovedInvestigationalHumanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). … Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)
Head Injury
go.drugbank.com/conditions/DBCOND0028168Synonyms: (Minor head injury) or (intracranial injury NOS without mention of open intracranial wound, with no loss of consciousness)Felbamate
go.drugbank.com/drugs/DB00949ApprovedAlternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites. … In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization).